Biotechnology market development

Unlike the pharmaceutical Industry, food processing Industries tend to be market driven rather that technology driven ( 7 ) and Is much more receptive to trends such as the demand for natural flavors. It Is anticipated that there will be more Investment In biotechnological flavor development especially as the technology proves Itself and that existing technology needs can be satisfied by these new approaches. 

D MD Newsletter. Westborough, MA Drug Market Development Pubbcations. ISSN 1053-1564. Targeted to biotechnology and pharmaceutical professionals. Covers the latest research and commercial developments and provides profiles of companies and technologies. 

MedMarkets. Foothill Ranch, CA MedMarket Diligence, LLC. Monthly. ISSN 1541-0862. Available electronically. A newsletter providing medical device market analysis. Each issue features two leading articles on a device market, plus updates on clinical findings, market developments, and the medical technology and biotechnology industries. 

Example (9) C, a biotechnology firm developed a new drug that substantially lowers blood pressure. Prior to marketing the drug, C incurs costs to test the product and obtain U.S. Food and Drug Administration (FDA) approval of the drug. 

Some observations on the factors relating to the biotechnology climates are necessary for understanding. Climates are the major areas such as governmental affairs, public acceptance, and overall business conditions that tend to affect the way an industry can develop apart from the scientific and marketing developments, which, of course, are the heart of biotechnology s progress to date. Each of these climatic areas is important and should be elaborated on. 

Although, MediChem is a biosecurity products manufacturer, its biotechnology-based R D capabilities are worth mentioning here. The attended markets include Medical, Laboratory, Veterinary, and Environmental sectors. Medicinal chemistry services and drug discovery form the basis of the company, though their capabilities might be applied in a broader range of sectors. These capabilities comprise the areas of Proteomics, Combinatorial and Computational Chemistry, Medicinal Chemistry, Enzymes, Process Development, Analytical and Separations Chemistry, Chemical Synthesis and Scale Up. 

After the approval of the first product, recombinant insulin, in 1982, progress in the development of new recombinant protein pharmaceuticals was slow ([10], Fig. 17.1). The number of biotechnology-derived drugs and vaccines approved by the US Food and Dmg Administration (FDA) has increased significantly only since 1995. More recently, sales of biologies have skyrocketed, e.g. from 900 million in 1999 to an estimated 3.5 billion in 2001 for monoclonal antibodies [11]. The annual global market for biopharmaceuticals is estimated to have increased from 12 billion US to 30 billion US in 2003 [12]. 500 candidate biopharmaceuticals are undergoing clinical evaluation and over one hundred protein-based therapeutics are in the... 

---